TP53 Mutations Confer High Risk in Patients With Myelofibrosis Undergoing HSCT
Researchers sought to determine the impact of TP53 mutations on HSCT outcomes in patients with myelofibrosis.
Researchers sought to determine the impact of TP53 mutations on HSCT outcomes in patients with myelofibrosis.
Researchers sought to determine whether combination therapy with pelabresib and ruxolitinib would lead to improvements in spleen reduction volume in myelofibrosis.
A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.
Researchers sought to determine if momelotinib provided better improvements in anemia in patients with myelofibrosis, compared with treatment with danazol.
A new study is investigating the use of navtemadlin in treatment of patients with myelofibrosis relapsed/refractory to JAK-inhibitor therapy.
Researchers sought to characterize the incidence and risk factors for thrombotic events in patients with secondary myelofibrosis.
The researchers uncovered higher-than-anticipated rates of thrombosis, hemorrhage, and transformation in their real-world cohort of MPN patients.
At 12 weeks, most patients had a reduction in spleen volume.
Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.